Xencor Inc (XNCR): Edgardo Jr Baracchini , Chief Business Officer of Xencor Inc sold 1,250 shares on Jul 11, 2016. The Insider selling transaction was reported by the company on Jul 13, 2016 to the Securities and Exchange Commission. The shares were sold at $18.13 per share for a total value of $22,662.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 30, 2016, Paul A Foster (Chief Medical Officer) sold 1,183 shares at $17.01 per share price.On Jun 30, 2016, Edgardo Jr Baracchini (Chief Business Officer) sold 1,250 shares at $15.10 per share price.Also, On May 25, 2016, Bassil I Dahiyat (President and CEO) sold 45,886 shares at $13.00 per share price.On Mar 3, 2016, John R Desjarlais (Sr. V.P., Research & CSO) sold 14,260 shares at $12.01 per share price.
Shares of Xencor Inc (XNCR) ended Monday, Jul 11, 2016 session in red amid volatile trading. The shares closed down -0.69 points or -3.71% at $17.93 with 2,35,516 shares getting traded. Post opening the session at $18.67, the shares hit an intraday low of $17.92 and an intraday high of $18.69 and the price vacillated in this range throughout the day. The company has a market cap of $731 M and the number of outstanding shares has been calculated to be 4,07,45,715 shares. The 52-week high of Xencor Inc is $24.82 and the 52-week low is $9.89.
Xencor Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. The Company uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases cancer and other conditions. The Company’s product pipeline includes three lead XmAb-engineered antibodies which include XmAb5871 XmAb7195 and XmAb5574/MOR208. XmAb5871 is indicated for the treatment of moderate-to-severe rheumatoid arthritis. XmAb7195 is the Company’s wholly owned program being developed for the treatment of severe asthma and allergic diseases. XmAb5574/MOR208 is being developed for the treatment of blood-based cancers.